Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $220

Benzinga · 07/22/2024 15:19
Cantor Fitzgerald analyst Olivia Brayer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and raises the price target from $150 to $220.